For patients with tumors pressed against delicate anatomy, like the spinal cord, the standard of care can be a choice between invasive surgery and no treatment at all. Microwave ablation, a minimally invasive technique that heats and destroys tumors from within, offers a third path. But conventional ablation devices radiate heat in all directions, a dangerous prospect when millimeters separate a tumor from critical nerves. A Kansas startup, Precision Microwave, is betting that a more precise, directional tool can open that path for more patients [MedCity News, 2021].
Founded in 2017 by engineers Austin Pfannenstiel and Punit Prakash, the company has operated in a quiet, research-heavy mode from its Manhattan, Kansas base [F6S]. Its core intellectual property is a side-firing microwave ablation applicator designed to radiate thermal energy in a controlled 120- to 180-degree arc, theoretically sparing healthy tissue on the shielded side [MedCity News, 2021]. The founders are inventors on patents owned by the company, and Prakash has been a subaward principal investigator on a National Science Foundation grant, signaling an academic rigor to the underlying physics [PMC]. The company’s primary outside backing comes from regional investor InvestMidwest [F6S].
A hardware wedge into complex oncology
The clinical bet is straightforward: by controlling the direction of the ablation zone, surgeons could treat tumors previously considered too risky for thermal therapy. This includes lesions abutting the spine, major blood vessels, or the bowel. The technology is purely hardware, a deliberate choice in a field increasingly crowded with AI diagnostic software. Precision Microwave’s differentiation is not in data analysis but in the physical design of the antenna and the multi-physics modeling that predicts its behavior in tissue [F6S]. The company partnered with product development firm Engenious Design, which built a functional demonstration unit in approximately three months for an estimated $200,000 [Medical Device News Magazine]. This suggests a focus on moving from concept to a tangible, testable device with capital efficiency.
The long road to a clinical tool
The ambition is clear, but the path for a new medical device is long, expensive, and fraught with regulatory milestones. Precision Microwave appears to be in the preclinical stage, focusing on computational modeling and animal evaluation [F6S]. Public records show no announced clinical trials, FDA clearances, or commercial partnerships with hospital systems. The competitive landscape is dominated by large, established players with approved products and extensive sales channels.
| Competitor | Key Product | Notes |
|---|---|---|
| Medtronic | Emprint Ablation System | Market leader with broad oncology portfolio and global reach. |
| NeuWave Medical | (Acquired by Johnson & Johnson) | Pioneered microwave ablation; part of J&J’s Ethicon division. |
| ECO Microwave | ECO-100A Series | Focus on microwave ablation for surgical oncology. |
| Solero | (Acquired by AngioDynamics) | Specializes in microwave ablation for soft tissue. |
For a small startup, the risks are multi-faceted. They must not only prove technical efficacy and safety but also navigate the capital-intensive process of FDA submission (likely a 510(k) clearance pathway) and build a commercial strategy to compete with giants. The company’s reported revenue is under $5 million with fewer than 25 employees, a profile consistent with a venture still in the development phase [ZoomInfo].
What success would look like for patients
The patient population in Precision Microwave’s crosshairs is those with surgically challenging solid tumors, particularly metastatic lesions in the spine, liver, and kidney. For these individuals, the current standard of care often involves a difficult calculus. Open surgery carries significant morbidity and recovery time. Radiation therapy has dose limitations and may not be suitable for all locations. Conventional, omnidirectional ablation is often contraindicated due to proximity to vital structures. The promise of a directional tool is to shrink that no-treatment zone, offering a minimally invasive, potentially curative option where one did not exist.
The next twelve months will be critical for visibility. Key signals to watch include the publication of peer-reviewed animal study data, the announcement of an FDA regulatory strategy, and any partnership with a larger medical device company for development or distribution. The company has shown it can win pitch competitions and secure early-stage backing [K-State ECE Uplink, 2017] [MedCity News, 2021]. The harder work,translating a promising antenna design into a clinically adopted tool,lies ahead.
Sources
- [F6S] Precision Microwave Company Profile | https://www.f6s.com/company/precisionmicrowave
- [ZoomInfo] Precision Microwave Inc Company Profile | https://www.zoominfo.com/c/precision-microwave-inc/551533831
- [MedCity News, 2021] INVEST Pitch Perfect winner spotlight: Precision Microwave's tech may alter challenging microwave ablation procedures | https://medcitynews.com/2021/05/invest-pitch-perfect-winner-spotlight-precision-microwaves-tech-may-alter-challenging-microwave-ablation-procedures/
- [K-State ECE Uplink, 2017] Austin Pfannenstiel takes 1st place in the Launch a Business Program! | https://blogs.k-state.edu/ece/2017/07/05/austin-pfannenstiel-takes-1st-place-in-the-launch-a-business-program/
- [Medical Device News Magazine] Engenious Design Partners With Precision Microwave | https://infomeddnews.com/engenious-design-partners-precision-microwave/
- [PMC] Directional microwave ablation in spine: experimental assessment of computational modeling | https://pmc.ncbi.nlm.nih.gov/articles/PMC11357707/
- [Medgadget, 2022] Engenious Design teamed up with Precision Microwave to create a directional microwave ablation generator | https://www.medgadget.com/2022/02/engenious-design-teamed-up-with-precision-microwave-to-create-a-directional-microwave-ablation-generator-that-treats-previously-inoperable-cancers.html